Glioblastoma multiforme (GBM) is the most malignant, aggressive and invasive form of central nervous system cancer. Despite improvements in chemotherapeutic agents, radiotherapy, micro-neurosurgical techniques and neuroimaging, the patients’ outcome remains dismal with a median survival of only about 14.6 months. The highly lethal nature of this tumour mainly originates from its highly infiltrative and dispersive nature. This project aims at the development of a reliable GBM cell exclusion zone migration assay that can be used to understand of the mechanisms that drive GBM cell migration, as well as, serve as a prognostic tool for the initial screening of drug efficacy.

Collaborators

Dr Colin Watts (Department of Clinical Neurosciences, Division of Neurosurgery, Addenbrooke's Hospital)

Dr Thierry Savin (Department of Engineering, Division of Mechanics, Materials and Design)